利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.013 秒)

    Balanced runner system for injection molding apparatus
    2.
    发明授权
    Balanced runner system for injection molding apparatus 失效
    平衡流道系统注塑机

    公开(公告)号：US3951375A

    公开(公告)日：1976-04-20

    申请号：US485083

    申请日：1974-07-02

    申请人： Peter John Lovell

    发明人： Peter John Lovell

    IPC分类号： B29C45/27 ,  B29F1/04

    CPC分类号： B29C45/2701 ,  B29C45/2725 ,  Y10S425/229

    摘要： A balanced runner system for injection moulding apparatus is disclosed. The runner system has an inlet, a plurality of runners and five gates. One of the gates is centrally located, the remaining gates being symmetrically spaced about the centrally located gate. The runners are such that the runner system is capable of supplying molten polymer to each gate at substantially the same rate. The runner system may be used to obtain a more uniform flow of molten polymer to a mould.

    摘要翻译： 公开了一种用于注射成型设备的平衡流道系统。 流道系统具有入口，多个流道和五个浇口。 其中一个门位于中心位置，其余的门对称地围绕位于中心的门。 浇道系统使得流道系统能够以基本上相同的速率向每个浇口供应熔融聚合物。 流道系统可用于获得更均匀的熔融聚合物流到模具中。

    Compounds
    3.
    发明授权
    Compounds 失效
    化合物

    公开(公告)号：US07026336B1

    公开(公告)日：2006-04-11

    申请号：US10130019

    申请日：2000-11-20

    申请人： David Kenneth Dean ,  Peter John Lovell ,  Andrew Kenneth Takle

    发明人： David Kenneth Dean ,  Peter John Lovell ,  Andrew Kenneth Takle

    IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  A61K31/4439 ,  A61P9/10

    CPC分类号： C07D409/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D417/14

    摘要： Compounds of formula (I) wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; Y is NR10R11, NR10C(Z)NR10R11, NR10COOR11 or NR10SO2R11; Ar is phenyl or a 5- or 6-membered heteroaryl ring either of which may be optionally substituted; n is 0, 1, 2, 3 or 4; and R1, R2, R3, R4, R10 and R11 have the meanings given in the description; and pharmaceutically acceptable salt thereof.

    摘要翻译： 其中X为O，CH 2，S或NH或X-R 1部分的式（I）化合物为氢; V是CH或N; Y是NR 10 R 11，NR 10 C（Z）NR 10 R 11， 其中，10个或更多个10个或更多个10个或更多个。 Ar是苯基或其中任一个可以被任选取代的5-或6-元杂芳基环; n为0,1,2,3或4; 和R 1，R 2，R 3，R 4，R 10， 和R 11具有说明书中给出的含义; 及其药学上可接受的盐。

    Sulfonamide derivatives as 5-HT7 receptor antagonists
    5.
    发明授权
    Sulfonamide derivatives as 5-HT7 receptor antagonists 失效
    磺酰胺衍生物作为5-HT7受体拮抗剂

    公开(公告)号：US06660751B1

    公开(公告)日：2003-12-09

    申请号：US09937043

    申请日：2001-09-20

    申请人： Peter John Lovell

    发明人： Peter John Lovell

    IPC分类号： C07D40104

    CPC分类号： C07D239/42 ,  C07D211/14 ,  C07D211/30 ,  C07D211/46 ,  C07D235/30 ,  C07D263/58 ,  C07D277/82 ,  C07D295/13 ,  C07D401/04 ,  C07D409/12 ,  C07D413/04 ,  C07D417/04

    摘要： The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. wherein: Q is phenyl or thienyl; R1 is halogen, hydroxy, C1-6alkyl, CF3, OCF3 or C1-6alkoxy; m is 0, 1, 2 or 3; R2 is C1-4alkyl; X is carbon or CH, is a single bond when X is nitrogen or CH or is a double bond when X is carbon, D is a single bond, C═O, O or CH2 subject to the proviso that when X is nitrogen then D is not oxygen; P is a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur; R3 is C1-6alkyl optionally substituted by NR4R5, aryl, arylC1-6alkyl, C1 6alkoxy, C1-6alkylthio, cyano, hydroxy, nitro, halogen, CF3, C2F5, NR4R5, CONR4R5, NR4COR5, S(O)pNR4R5, CHO, OCF3, SCF3, CH2OR6, CO2R6 or COR6 where p is 0, 1 or 2 and R4, R5 and R6 are independently hydrogen, C1-6alkyl, aryl or arylC1-6alkyl; n is 0, 1, 2 or 3.

    摘要翻译： 本发明涉及具有5-HT7受体拮抗剂活性的新型磺酰胺化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它病症中的用途。其中Q为苯基或噻吩基; R 1为 卤素，羟基，C 1-6烷基，CF 3，OCF 3或C 1-6烷氧基; m为0,1,2或3; R 2为C 1-4烷基; X为碳或CH，CUSTOM-CHARACTER FILE =“US06660751- 20031209-P00900.TIF“当X是氮或CH或 “X”是碳时，双键，“D”是单键，“US06660751-20031209-P00900.TIF”ALT =“custom character”HE =“20”WI =“20”ID =“CUSTOM-CHARACTER-00002”/> ，C = O，O或CH 2，条件是当X是氮时，D不是氧; P是含有1至3个选自氧，氮和硫的杂原子的5或6元杂芳基环，或苯并稠合的杂芳基环 含有1至3个选自氧，硝基的杂原子 基和硫; R 3是任选被NR 4 R 5，芳基，芳基C 1-6烷基，C 1-6烷氧基，C 1-6烷硫基，氰基，羟基，硝基，卤素，CF 3，C 2 F 5，NR 4，R 5，CONR 4 R 5，NR 4 COR 5，S（O）p NR 4 R 5，CHO，OCF 3，SCF 3，CH 2 O 6， CO 2 R 6或COR 6，其中p是0,1或2，R 4，R 5和R 6独立地是氢，C 1-6烷基，芳基或芳基C 1-6烷基; n是0， 1，2或3。

    Novel Compounds
    6.
    发明申请
    Novel Compounds 审中-公开
    新型化合物

    公开(公告)号：US20100227870A1

    公开(公告)日：2010-09-09

    申请号：US12663739

    申请日：2008-06-12

    申请人： Massimo Gianotti ,  Jag Paul Heer ,  Peter John Lovell ,  Catia Seri ,  Ben Gerald Tehan

    发明人： Massimo Gianotti ,  Jag Paul Heer ,  Peter John Lovell ,  Catia Seri ,  Ben Gerald Tehan

    IPC分类号： A61K31/4965 ,  C07D241/04 ,  A61P25/18

    CPC分类号： C07D295/185

    摘要： The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating diseases and conditions mediated by positive allosteric modulation of the G-protein coupled metabotropic subtype 5 receptor (mGluR5), such as neurological and psychiatric disorders, for example schizophrenia. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

    摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，用于治疗由G-蛋白偶联的代谢型5型受体（mGluR5）的正性变构调节介导的疾病和病症，例如神经和精神疾病，例如精神分裂症 。 此外，本发明涉及含有衍生物的组合物及其制备方法。